Clinical trial

The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot

Name
LB.02.01/Vll/011/KEP011/2022
Description
Congenital heart disease (CHD) is the most common congenital abnormality found in newborns with Tetralogy of Fallot (TOF) being the most common cyanotic CHD. Total correction of TOF was performed using a cardiopulmonary bypass (CPB) machine. However, the use of CPB has a negative effect that causes inflammation and myocardial injury. Myocardial protection in patients undergoing total correction of TOF surgery is more difficult than other cyanotic CHD due to a hypertrophic right ventricular condition. Dexmedetomidine (DEX) is a selective α-2 adrenergic, which has major effects including hypnosis, sedation, and analgesia as well as cardiovascular effects. The sedation is induced by stimulating the α-2 adrenergic receptor in the locus coeruleus (LC) in the pons cerebri. DEX also increases the level of GABA and Galanin and reduces endogenous norepinephrine. The lower level of endogenous norepinephrine decreases the afterload of the ventricles, increases cardiac output, and reduces myocardial injury as a result. Furthermore, the peripheral effects of DEX can reduce myocardial ischemia-reperfusion (MIR) by inhibiting NF-кB pathway activation and reducing the number of pro-inflammatory cytokines released. Thus, the administration of DEX can prevent myocardial necrosis and apoptosis, also reducing reperfusion injury when using CPB machines. Research related to the effectiveness of administering DEX as a myocardial protector in classic TOF patients undergoing elective total correction cardiac surgery in Indonesia is less reported. The aim of this study is to determine the effectiveness of DEX as myocardial protector in classic TOF patients undergoing elective total correction cardiac surgery.
Trial arms
Trial start
2022-10-10
Estimated PCD
2023-04-10
Trial end
2023-06-10
Status
Completed
Phase
Early phase I
Treatment
Dexmedetomidine Hcl 100 Mcg/mL Inj
Priming dose of 0.5 mcg/kg in a 5 ml syringe mixed in priming fluid and 0.25 mcg/kg/hour DEX infusion diluted in 0.9% NaCl 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
Arms:
DEX Group
Other names:
Precedex, Kabimidine
Placebo
Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
Arms:
Control Group
Other names:
NaCl 0.9%
Size
66
Primary endpoint
Serum Troponin I at baseline
5 minutes after induction of anesthesia (T1)
Serum Troponin I at 1 hour after cardiopulmonary bypass
1 hour after cardiopulmonary bypass (T2)
Serum Troponin I at 6 hours after cardiopulmonary bypass
6 hours after cardiopulmonary bypass (T3)
Serum Troponin I at 24 hours after cardiopulmonary bypass
24 hours after cardiopulmonary bypass (T4)
Serum IL-6 at baseline
5 minutes after induction of anesthesia (T1)
Serum IL-6 at 1 hour after cardiopulmonary bypass
1 hour after cardiopulmonary bypass (T2)
Serum IL-6 at 6 hours after cardiopulmonary bypass
6 hours after cardiopulmonary bypass (T3)
Serum IL-6 at 24 hours after cardiopulmonary bypass
24 hours after cardiopulmonary bypass (T4)
Eligibility criteria
Inclusion Criteria: * The patient's parents or person in charge is willing to participate in the study * Patients with classic TOF undergoing elective total correction cardiac surgery * Aged 1 month - 18 years old Exclusion Criteria: * The patient experiences a change in the surgical plan from elective to immediate or emergency * Patients with preoperative infection characterized by procalcitonin \>0.5ng/mL * Patients with impaired liver function characterized by an increase in Serum Glutamic Oxaloacetic Transaminase (SGOT)/Serum Glutamic Pyruvic Transaminase (SGPT) more than 1.5 times the upper limit of normal * Impaired renal function characterized by creatinine \> 2 mg/dL * Patients with coagulation disorders characterized by International Normalized Ratio (INR) \> 1.5 Drop-out Criteria: * Duration of CPB and/or Aortic cross-clamp time exceeding 120 minutes * Surgery requires more than two attempts of CPB * Patient fails to wean from CPB * Patient requires ECMO (Extracorporeal Membrane Oxygenator) postoperatively * Patients with postoperative reperfusion injury characterized by pulmonary hemorrhage * Patients with residual lesions in the form of moderate-severe pulmonary stenosis and moderate-severe pulmonary regurgitation. * Patient dies on the operating table
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 66, 'type': 'ACTUAL'}}
Updated at
2023-08-24

1 organization

1 product

1 drug

3 indications